

Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI)

Submission date 26/11/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 06/06/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 11/04/2019	Condition category Neonatal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Luca Filippi

Contact details
A. Meyer University Childrens Hospital
Neonatal Intensive Care Unit
Department of Perinatal Medicine
Viale Pieraccini, 24
Florence
Italy
I-50139
+39 (0)55 566 2434
l.filippi@meyer.it

Additional identifiers

Clinical Trials Information System (CTIS)
2010-018627-25

ClinicalTrials.gov (NCT)
NCT01241019

Protocol serial number

2010-018627-25

Study information

Scientific Title

Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a pilot study of the Neonatal Neuroprotection of Asphyxiated Tuscan Infants (NeoNATI) Network

Acronym

NeoNATI

Study objectives

To determine whether the administration of topiramate to newborns with hypoxic-ischemic encephalopathy (HIE) potentiates the neuroprotective effect of treatment with hypothermia

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of Azienda Ospedaliero-Universitaria "A. Meyer" of Florence; approved on January 10, 2010

Study design

Two-centre interventional pilot randomised controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hypoxic Ischemic Encephalopathy (HIE)

Interventions

Newborns with moderate to severe hypoxic ischaemic encephalopathy at two centres in Florence and Pisa will be randomised to one of the following treatment arms:

1. Intervention group: Newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia will receive topiramate (TPM) 10 mg/kg once a day, administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
2. Control group: Newborns with hypoxic ischemic encephalopathy will be treated only with mild hypothermia

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Topiramate

Primary outcome(s)

1. Survival rate
2. General movements at 7-10 days and after 12 weeks of life
3. Neurological examination including:
 - 3.1. Gross motor function at 7-10 days, 12 weeks, 6 months, 12 months, 18 months of life using Dubowitz neurological examination and Bayley test
 - 3.2. Acoustic functions at 7-10 days, 6 months, 12 months and 18 months of life
 - 3.3. Visual functions at 7-10 days, 6 months, 12 months and 18 months of life

Key secondary outcome(s)

Efficacy of treatment with topiramate for improving neuroradiological outcome at 3 and 12 months of life using cerebral Magnetic Resonance Imaging (MRI) (standard, with diffusion tensor imaging and with Spectroscopy)

Completion date

01/02/2012

Eligibility

Key inclusion criteria

1. Newborns with gestational age > 36 weeks and birth weigh > 1800 g with at least 1 of the following:
 - 1.1. Apgar score < 5 at 10 minutes
 - 1.2. Persisting need for resuscitation, including endotracheal intubation or mask ventilation 10 minutes after birth
 - 1.3. Acidosis (pH <7.0, base deficit >-16 mmol/L in umbilical cord blood or arterial, venous or capillary blood) within 60 minutes from birth
2. Moderate to severe encephalopathy, consisting of altered state of consciousness (irritability, lethargy, stupor, or coma) and > 1 of the following signs:
 - 2.1. Hypotonia
 - 2.2. Abnormal reflexes, including oculomotor or pupil abnormalities
 - 2.3. Absent or weak suck
 - 2.4. Clinical seizures
3. Abnormal ambulatory electroencephalogram (aEEG)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Neonate

Sex

All

Key exclusion criteria

1. Congenital abnormalities
2. Congenital viral infections
3. Evidence of encephalopathy other than HIE

Date of first enrolment

09/02/2010

Date of final enrolment

01/02/2012

Locations

Countries of recruitment

Italy

Study participating centre

A. Meyer University Childrens Hospital

Florence

Italy

I-50139

Sponsor information

Organisation

A. Meyer University Childrens Hospital (Italy)

ROR

<https://ror.org/01n2xwm51>

Funder(s)

Funder type

Government

Funder Name

General Directorate for Health Law and Policy of Solidarity, Area Coordinating Health, Division of Research, Development and Labor Protection in the Region of Tuscany (Italy) - Regional Health Research Program 2009

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2018	16/01/2019	Yes	No
Protocol article	protocol	05/09/2012		Yes	No